Investigational Drug Adcetris to Treat Malignant Mesothelioma
Type: Pleural, Peritoneal, Pericardial Mesothelioma
Researchers at the MD Anderson Cancer Center are investigating the use of the drug adcetris (brentuximab vedotin) to combat mesothelioma.
Treating Patients with Adcetris
Adcetris consists of two parts: a targeted therapy and a chemotherapy agent. This drug is commonly used in patients with hodgkin lymphoma and anaplastic large cell lymphoma.
Patients with any primary site of mesothelioma and any cell type are eligible for this trial. However, a participant must test positive for the CD30 protein.
- Targeted Therapy– One component of adcetris is a type of targeted therapy. It targets the CD30 antigen on the surface of cancer cells and attaches to the cell. Once it is inside of the cell, it stops them from dividing. This disruption eventually leads to cancer cell death.
- Chemotherapy – Adcetris also contains an antineoplastic (chemotherapy) agent. Chemotherapy is one of the most standard forms of treatment that is used for combating mesothelioma. Chemotherapy works by attacking cells that replicate quickly, like cancer cells.
Since adcetris works by interfering with the growth and spread of cancer cells that are inside the body, researchers believe that this investigational approach may help patients that are combating mesothelioma.
Get Help Enrolling in This Trial
Reasons to get involved in this trial include:
- Receiving proven life-extending treatment
- Get treated at a top cancer center
- Physical exams and routine tests guarantee participant safety
About the Trial
This clinical trial is currently recruiting. The study will enroll about 50 participants.
The goal of this trial is to see if the drug adcetris (brentuximab vedotin) can control mesothelioma. During this phase 2 study, researchers will also be analyzing the safety of this drug.
Investigational Drug Adcetris
In previous clinical trials, some side effects that patients reported while taking adcetris were:
- Tingling or numbness in hands or feet
Using the drug adcetris to combat mesothelioma is considered investigational. This means that researchers are still trying to investigate both its safety and effect it has on mesothelioma patients.
What to Expect
The drug adcetris will be administered to patients intravenously every 21 days (about a 3-week cycle). This process will take about 30 minutes.
On the first day of each 3-week cycle, a patient can expect to have a physical exam and to have their blood drawn for routine tests. These routine tests will determine if a patient can still participate in the clinical trial.
Every 6 weeks a patient will have a PET-CT scan. This scan will allow doctors to check the status of their disease and to see how they are responding to the investigational drug.
A patient will be able to remain in the clinical trial until they personally withdraw from the study or if they experience severe issues such as:
- Unacceptable toxicity
- Disease progression
- Intolerable side effects
A patient will receive a follow up 30 days after taking their last dose of adcetris.
Is This Trial for You?
Patients eligible for this trial:
- Must have malignant mesothelioma
- May be chemo-naive or chemo-refractory
- Are not eligible for surgery
- May have participated in any line of prior therapy
- May have any cell type (histology)
A few criteria that will make a patient ineligible for this clinical trial are:
- A patient cannot participate in this clinical trial if they have received any other type of investigational drugs within 14 days of their enrollment.
- They must also have no other history of a malignancy within 2 years or hematologic malignancy within 3 years.
Location: MD Anderson Cancer Center
The clinical trial is taking place at the University of Texas MD Anderson Cancer Center in Houston, Texas. The MD Anderson Cancer Center offers mesothelioma patients treatment options such as extrapleural pneumonectomy and pleurectomy surgery options. The center is also known for its expertise in clinical trials.
Head of Trial: Dr. Anne Tsao
Dr. Anne Tsao is the director of the mesothelioma and thoracic chemo-radiation programs at the MD Anderson Cancer Center. She is a specialist in treating thoracic cancers, such as pleural mesothelioma.
If you have any questions or concerns about this clinical trial, please feel free to contact Mesothelioma Guide’s nurse and patient advocate, Jenna Campagna.